This report will be delivered in 3-5 working days.

Introduction to Asia-Pacific (APAC) Nucleic Acid Therapeutics CDMO Market
The APAC Nucleic Acid Therapeutics CDMO Market is expected to grow at a CAGR of 13.92% from $0.97 billion in 2022 to $4.04 billion by 2033 in the forecasted period of 2023-2033. The increasing incidence of hereditary and chronic illnesses, improvements in nucleic acid production, a rise in regulatory approvals, and an expanding CDMO manufacturing infrastructure are all expected to contribute to the significant growth of the APAC nucleic acid therapies CDMO market in the years to come. With the increasing demand for nucleic acid therapeutics, CDMOs will be essential in enabling patients all around the world to access these cutting-edge treatments.

Market Introduction
With the rising incidence of genetic and chronic illnesses, growing regulatory approvals, growing CDMO manufacturing infrastructure, and encouraging government initiatives, the APAC nucleic acid therapeutics CDMO market is expected to grow significantly in the next years. With the increasing demand for nucleic acid therapeutics, CDMOs will be essential in enabling patients all around the world to access these cutting-edge treatments.

Market Segmentation:

Segmentation 1: by Chemical Synthesis Method

  • Solid-Phase Oligonucleotide Synthesis
  • Liquid-Phase Oligonucleotide Synthesis


Segmentation 2: by Country

  • China
  • Japan
  • India
  • Australia
  • Rest-of-Asia-Pacific


Demand – Drivers and Limitations

The following are the drivers for the Asia-Pacific nucleic acid therapeutics CDMO market:

  • Increasing Presence of Established Players in the Region
  • Funding Support and Investments from the Government
  • Low Cost of Manufacturing


The market is expected to face some limitations as well due to the following challenges:

  • Lack of Expertise in Developing Nucleic Acid Therapeutics


How can this report add value to an organization?
Product/Innovation Strategy: The nucleic acid therapeutics CDMO market has been extensively segmented based on various categories, such as product, chemical synthesis method, disease type, technology, and end users. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: Key players in the Asia-Pacific nucleic acid therapeutics CDMO market analysed and profiled in the study involve established players that offer various kinds of nucleic acid therapeutics CDMO products.

The Asia-Pacific nucleic acid therapeutics CDMO market has witnessed several investments for the expansion of CDMO manufacturing units by the market players. The expansion is aimed at increasing the manufacturing capacity. To meet the growing demand for their services, CDMOs are expanding their manufacturing units and investing in new technologies. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

  • Asymchem Inc.
  • BioCina
  • CMIC HOLDINGS Co., Ltd.
  • Kaneka Corporation
  • Nippon Shkubai Co., Ltd
  • Nitto Group
  • ST Pharm